Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors.

Kahen EJ, Brohl A, Yu D, Welch D, Cubitt CL, Lee JK, Chen Y, Yoder SJ, Teer JK, Zhang YO, Wallace MR, Reed DR.

Oncotarget. 2018 Apr 27;9(32):22571-22585. doi: 10.18632/oncotarget.25181. eCollection 2018 Apr 27.

2.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

3.

Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.

Kahen E, Yu D, Harrison DJ, Clark J, Hingorani P, Cubitt CL, Reed DR.

Cancer Chemother Pharmacol. 2016 Aug;78(2):313-23. doi: 10.1007/s00280-016-3077-8. Epub 2016 Jun 20.

4.

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM.

Mol Clin Oncol. 2016 Mar;4(3):399-404. Epub 2016 Jan 7.

5.

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR.

Sci Rep. 2015 Nov 25;5:16991. doi: 10.1038/srep16991.

6.

Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC.

J Clin Invest. 2014 Jun;124(6):2585-98. doi: 10.1172/JCI73448. Epub 2014 May 8.

7.

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM.

Semin Cancer Biol. 2014 Aug;27:62-73. doi: 10.1016/j.semcancer.2014.03.001. Epub 2014 Mar 12. Review.

8.

Rapid screening of novel agents for combination therapy in sarcomas.

Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR.

Sarcoma. 2013;2013:365723. doi: 10.1155/2013/365723. Epub 2013 Oct 24.

9.

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.

J Cancer. 2013 Sep 10;4(8):614-25. doi: 10.7150/jca.7080. eCollection 2013.

10.

MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines.

Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M.

Cancer Biol Ther. 2013 Oct 1;14(10):932-6. doi: 10.4161/cbt.25939. Epub 2013 Aug 5.

11.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.

J Med Chem. 2013 May 23;56(10):3768-82. doi: 10.1021/jm301234k. Epub 2013 May 6.

12.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

13.

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207. Epub 2012 May 17.

14.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26.

15.

Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Gray J, Cubitt CL, Zhang S, Chiappori A.

Cancer Biol Ther. 2012 Jun;13(8):614-22. doi: 10.4161/cbt.19848. Epub 2012 Jun 1.

16.

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM.

Invest New Drugs. 2011 Dec;29(6):1381-9. doi: 10.1007/s10637-010-9479-2. Epub 2010 Jul 20.

17.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI.

Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c.

PMID:
19434004
18.

Molecular genetics of the BK virus.

Cubitt CL.

Adv Exp Med Biol. 2006;577:85-95. Review.

PMID:
16626029
19.

Chinese strains (Type 7) of JC virus are afro-asiatic in origin but are phylogenetically distinct from the Mongolian and Indian strains (Type 2D) and the Korean and Japanese strains (Type 2A).

Cui X, Wang JC, Deckhut A, Joseph BC, Eberwein P, Cubitt CL, Ryschkewitsch CF, Agostini HT, Stoner GL.

J Mol Evol. 2004 May;58(5):568-83.

PMID:
15170260
20.

BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis.

Drachenberg CB, Papadimitriou JC, Wali R, Cubitt CL, Ramos E.

Am J Transplant. 2003 Nov;3(11):1383-92.

21.

JC virus genotypes in the western Pacific suggest Asian mainland relationships and virus association with early population movements.

Yanagihara R, Nerurkar VR, Scheirich I, Agostini HT, Mgone CS, Cui X, Jobes DV, Cubitt CL, Ryschkewitsch CF, Hrdy DB, Friedlaender JS, Stoner GL.

Hum Biol. 2002 Jun;74(3):473-88. Erratum in: Hum Biol. 2003 Feb;75(1):141.

PMID:
12180767
22.

Predicted amino acid sequences for 100 JCV strains.

Cubitt CL, Cui X, Agostini HT, Nerurkar VR, Scheirich I, Yanagihara R, Ryschkewitsch CF, Stoner GL.

J Neurovirol. 2001 Aug;7(4):339-44.

PMID:
11517413
23.

Synthesis of type II interleukin-1 receptors by human corneal epithelial cells but not by keratocytes.

Cubitt CL, Lausch RN, Oakes JE.

Invest Ophthalmol Vis Sci. 2001 Mar;42(3):701-4.

PMID:
11222530
24.
25.

Differences in interleukin-6 gene expression between cultured human corneal epithelial cells and keratocytes.

Cubitt CL, Lausch RN, Oakes JE.

Invest Ophthalmol Vis Sci. 1995 Feb;36(2):330-6.

PMID:
7843904
27.

IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes.

Cubitt CL, Tang Q, Monteiro CA, Lausch RN, Oakes JE.

Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3199-206.

PMID:
7691777
29.

Supplemental Content

Loading ...
Support Center